Hold CL at modest Underweight sizing (≤2% of portfolio, below benchmark weight for a 0.32-beta defensive)
The 9/24 binding lesson is the governing constraint: default to Hold with optional hedge rather than trim when the bearish signal cluster meets intact franchise fundamentals. The trader's SELL with $87.87 stop is structurally catastrophic and rejected — the stop sits one cent above the 200 SMA where mean-reversion bounces cluster in a 0.32-beta defensive. Patience with a deadline is the correct stance; the 2.46% dividend yield provides carry during the wait. The Q3 Oct 23 earnings is the binary catalyst; prior decision architecture preserved franchise carry through identical setups on 9/28 and 10/01-10/05.
| Position | Action |
|---|---|
| Current position above modest Underweight threshold | Trim to 50-75% of normal staples allocation, magnitude-capped at 5-7%, to reach ~93-95% of benchmark |
| Price at or above $88.50-$90.00 relief rally zone (50 SMA resistance) | Execute conditional trim ONLY into this relief rally zone |
| Price at $86.19 | No active trim (1.4% above structural support at $84.26) |
| Position sizing | Maintain ≤2% of portfolio (below benchmark weight) |
The technical "breakdown" is actually a late-stage base-building setup with 38% ATR compression, MACD histogram at zero, and improving RSI (44.59) signaling momentum exhaustion rather than trend continuation, while fundamentals support a BUY with Q1 2026 revenue acceleration to +5.0% YoY and forward P/E of 21.3x.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 85.82 | neutral |
| close_50_sma | 89.54 | bearish |
| close_200_sma | 87.87 | bearish |
| macd | -1.22 | bearish |
| macd_histogram | -0.00 | neutral |
| rsi | 44.59 | neutral |
| atr | 1.51 | neutral |
| vwma | 86.30 | bearish |
Support: 84.26 · 84.3 · 84.33 | Resistance: 87.87 · 89.54
The technical setup is neutral-to-cautiously bullish for a counter-trend bounce but not yet a confirmed trend reversal. The 50 SMA (89.54) and 200 SMA (87.87) remain above price, confirming bearish medium-term structure, but MACD histogram improvement and RSI recovery from oversold suggest downside momentum is exhausting. ATR compression (down ~38% from 2.45 to 1.51) points to potential volatility expansion ahead. Key trigger for upgrade: daily close above $87.87 with MACD histogram positive and RSI > 50. Key trigger for downgrade: close below $84.26 invalidating the bounce thesis.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Reclaim above $87.87 on any 200 SMA reclaim
Then: Reassess position upon 200 SMA reclaim above $87.87
CL is undervalued at 21.3x forward P/E with 5% FCF yield
↩ rebuts: “Bear anchors on TTM P/E of 34.4x and calls CL expensive”
EV: +15-20% (to $92-94 from current $86.19)
CL is a structurally broken defensive name trading at 34x trailing earnings with a confirmed downtrend, one noisy revenue quarter, ongoing impairment risk in Hill's Pet, a hollowed balance sheet, and macro headwinds from higher-for-longer rates and strong dollar—making the risk/reward unfavorable for new longs until the 200 SMA is reclaimed.
· concedes: The bull's momentum narrative is 'tactically appealing' and 'craft'; The deleveraging and capital return story is 'correct, but it's a snapshot'; The 52-week midpoint math (below midpoint, not at top) is 'correct but irrelevant' to forward direction; One 5% quarter is a quarter, not a thesis—the bull's framing of it as secular is the problem
→ vs neutral: Analysis paralysis destroys returns: MACD LINE at negative 1.22 signals ongoing downtrend not reversal, ATR compression at $1.51 (down 38%) typically resolves to downside expansion in downtrends, waiting for full confirmation (200 SMA reclaim, MACD positive, RSI above 50) means buying at $89 where smart money distributes
Market Cap
$69,553,324,032
Beta
0.322
52-Week Range
$74.55 – $99.33
50-Day MA
$89.55
200-Day MA
$88.51
Dividend Yield
2.46%
Current Ratio
1.026
P/E (TTM)
34.35
Forward P/E
21.29
Price/Book
294.76
PEG Ratio
1.57
EV/EBITDA
~16.7x
Revenue 2025 (TTM)
$21,047M
Revenue Q1 2026
$5,361M
Gross Margin
~60.4%
Operating Margin
20.97%
Profit Margin (TTM)
9.68%
ROE
267.4%
ROA
15.84%
EPS (TTM)
$2.54
Forward EPS
$4.10
Book Value/Share
$0.30
Revenue CAGR (2021-25)
~4.1%
FCF Growth 2022→2025
+95%
TTM Free Cash Flow
$3.46B
FCF Yield (TTM)
~5.0%
Net Debt
$6.49B
Debt/EBITDA
~1.65x
Cash
$1.37B
Total Debt
$8,554M
Stockholders' Equity
$236M
Working Capital
($1,144M)
Annual Dividends
$1.82B
Annual Buybacks
~$1.2-1.7B
Dividend Payout
~58% of FCF
CapEx as % of Revenue
~2.7%
EBITDA Margin
~23.7%
Goodwill & Intangibles
$4,658M
Strengths
Concerns
Colgate-Palmolive is a high-quality defensive compounder trading at a premium TTM P/E of 34.35x but with a more reasonable Forward P/E of 21.29x based on expected EPS growth from $2.54 to $4.10. The company generates exceptional free cash flow ($3.46B TTM, 5.0% yield) with best-in-class 21% operating margins and a disciplined capital return program combining dividends and buybacks. Despite headwinds from FX exposure and a 2025 impairment charge, revenue is accelerating (5.0% YoY in Q1 2026), net debt is declining, and the low-beta profile makes CL suitable as a defensive portfolio cornerstone.
Macro: Higher-for-longer rate environment with 10Y at highest since 2002; Fed officials signaling inflation still too elevated; Polymarket pricing 96% probability of zero rate cuts in 2026; S&P/Nasdaq at record highs but narrow tech leadership; higher rates pummeling consumer discretionary stocks; September jobs missed; Polymarket recession odds: US 6% (down 2pp), UK 7%, Japan 4%; Iran-related supply-side inflation shock broadening beyond oil.